N4 Pharma Share Discussion Threads

[pwal] 18/12/2023 08:26

From the RN:Given the complexities involved in oral delivery this early success with Nuvec(R) represents a potentially massive opportunity and point of difference for Nuvec(R) and its use as delivery system to target multiple diseases.

[dplewis1] 12/12/2023 15:57

He's not a director.. just some bloke with a terrible average price

[tomboyb] 12/12/2023 15:37

Interesting -

Could see 1p+ -

[pwal] 11/12/2023 19:45

DAVID FARRIER I believe.

[dplewis1] 11/12/2023 19:26

Which director?

[pwal] 08/12/2023 11:51

No one commenting on the director buy?

[dplewis1] 07/12/2023 16:00

Your old mate Hugh has averaged down today though.. lol

[nobbygnome] 07/12/2023 07:50

What a load of nonsense this morning. They are spending lots of time and money getting nowhere. The Nuvec particles remain an awfully long way from being commercialised and of course still not actually gone into a human.

This really is a lifestyle company…

[dplewis1] 14/11/2023 10:53

It's not looking good is it Dave

[ronpharma] 14/11/2023 06:55

New tech looks good, but would need a few months to get data in order. Hopefully nigel can.

[don carter] 29/9/2023 14:11

Out to MXCT.

[blackhorse23] 28/9/2023 15:14

Out from here & going to buy GATC

[jusjusjus] 28/9/2023 10:49

they haven't even attempted to say who the shares have been placed with, but whoever it is they can buy cheaper from the market - ha ha!

[bingham] 28/9/2023 10:36

Not for the share price it seems.

[pwal] 28/9/2023 09:58

The acquisition must be a good thing!

[pwal] 20/9/2023 11:31

Nice to see some movement.

[tomboyb] 25/7/2023 08:13

25/07/2023 7:00am
UK Regulatory (RNS & others)

N4 Pharma (LSE:N4P)
Intraday Stock Chart

Tuesday 25 July 2023

Click Here for more N4 Pharma Charts.
TIDMN4P

RNS Number : 0209H

N4 Pharma PLC

25 July 2023

25 July 2023

N4 Pharma Plc

("N4 Pharma" or the "Company")

Patent Grant and Board Change

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, announces two operational updates.

Granting of further US patent

The University of Queensland has informed the Company that it has been notified by the US patent attorney of the granting of its further patent application in relation to Nuvec(R) in the United States.

N4 Pharma has licensed the exclusive worldwide rights to Nuvec(R) from the University of Queensland for therapeutic uses in humans and animals.

This granted patent in the US is for the composition of matter of the nanoparticle itself and will sit alongside the first US patent grant announced on 31 January 2022, which concerned how the nanoparticle is made using a broad description of the manufacturing process used by the Company.

Board Change

The Company announces that John Chiplin, currently Non-Executive Chairman, is retiring from the Board for personal reasons. Chris Britten, currently a Non-Executive Director of the Company, will assume the role of Non-Executive Chairman of N4 Pharma with effect from 1 August 2023.

The Company will initiate a search process to identify an additional Non-Executive Director and will provide an update as and when appropriate.

Nigel Theobald, Chief Executive Officer of the Company, commented:

" We are delighted to receive notification of this further patent grant for our licensed patent in this critical and influential market.

"The granting of this patent now means the patents in the US are on equal terms to those granted in other territories for both the particle itself and how it is made.

"On behalf of the Board, I would like to thank John f

[tomboyb] 25/7/2023 08:12

Punted a few -

Good luck -

[earwacks] 25/7/2023 08:04

USA patent news update is very welcome strengthening of intellectual property. Research in America is funded a thousand times more in this area. So when does the money runnout? That is the beauty of N4, there are no expensive lab costs they license or lend at the moment the nano technology to the drug companies. At some stage it will become an industry standard in the treatment of cancers and delivery of vaccinations. Looks like we are still ahead of the game in this area and the professor at Queens uni in Australia who are partners has been awarded a grant to further research at no cost to N4p. The hard miles have been done in establishing the technology property and establishing up to date world wide patents.

[nobbygnome] 06/7/2023 14:30

I see it’s going well here. When does the money run out?

[featherby81] 08/6/2023 07:21

They will always have to do in vitro work Nobby, any new compound that a future client wants to test on Nuvec will need to go through these basic procedures to test binding, compatibility ect.
The current in vitro work is being assessed by ‘interested parties’ so they have to get it right.

[nobbygnome] 12/5/2023 10:58

I despair that they are still doing in vitro work! Then we will get the animal models….will the particles ever go into a human?